Neonatal Withdrawal Symptoms After Olanzapine Exposure
Newborns exposed to olanzapine during the third trimester may develop extrapyramidal and/or withdrawal symptoms including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder, with symptom onset typically within hours to days after birth and variable severity. 1
Clinical Presentation
The FDA drug label for olanzapine explicitly warns that neonates exposed during the third trimester are at risk for a constellation of symptoms that include:
Neurological/Motor Symptoms
- Tremor - abnormal muscle movements
- Hypertonia (increased muscle tone) or hypotonia (decreased muscle tone)
- Agitation and irritability
- Somnolence (excessive sedation)
Autonomic/Feeding Symptoms
- Respiratory distress
- Feeding disorder or poor feeding
These symptoms represent both extrapyramidal effects and withdrawal phenomena 1.
Timing and Duration
Symptoms typically manifest within hours to days after birth, with severity varying considerably. Some neonates recover within hours or days without specific treatment, while others require prolonged hospitalization 1. The AAP guideline framework for neonatal drug withdrawal notes that sedative-hypnotic withdrawal (which shares mechanistic features with antipsychotics) classically appears after the first few days of life, with onset potentially delayed up to 12 days for diazepam 2.
Clinical Context from Research
A 2011 prospective study found that among 30 newborns exposed to olanzapine in utero, neonatal symptoms occurred in 20% (6/30), with a withdrawal syndrome specifically identified in 10% (3/30) 3. This aligns with a 2023 registry study showing that approximately 32.6% of SGA-exposed infants (including olanzapine) experienced at least one sign of poor neonatal adaptation syndrome (PNAS) 4.
A 2025 study identified that maternal use of antipsychotics was a significant risk factor for withdrawal symptoms (adjusted OR 1.77), with risk further increased when mothers received ≥3 neuropsychiatric drugs concurrently 5.
Breastfeeding Exposure
For infants exposed through breast milk, the FDA label and research report similar symptoms: excess sedation, irritability, poor feeding, and extrapyramidal symptoms (tremors and abnormal muscle movements) 1, 3. In the 2011 breastfeeding study, most infants (82.3%) had no adverse events, though somnolence (3.9%), irritability (2%), tremor (2%), and insomnia (2%) were reported 6.
Clinical Management Approach
Monitor all exposed neonates for at least 48-72 hours after birth for development of symptoms 1. The observation period should extend until symptoms fully resolve if they develop 7.
Monitoring Protocol
- Use structured assessment tools (e.g., Finnegan scoring list) every 8 hours administered by trained nurses
- Paediatrician interpretation of scores required
- Rule out alternative diagnoses (infection, neurologic problems, hypoglycemia)
- Consider toxicological screening if intoxication suspected
Treatment Strategy
Most cases are mild, self-limiting, and require only supportive care:
- Frequent small feedings
- Swaddling
- Increased skin-to-skin contact with mother
- Breastfeeding may be protective (based on SSRI data extrapolation) 7
For severe symptoms, admit to neonatal care unit; phenobarbital is a safe therapeutic option when pharmacologic intervention is needed 7.
Important Caveats
The evidence base specifically for olanzapine is limited compared to opioids and SSRIs. The provided guidelines [2-2] focus primarily on opioid withdrawal, while olanzapine data comes from FDA labeling and smaller observational studies. The mechanism differs: olanzapine withdrawal likely involves dopaminergic and serotonergic dysregulation rather than the noradrenergic surge seen with opioids 2.
Do not discontinue necessary maternal antipsychotic treatment due to these risks, as untreated maternal psychiatric illness carries substantial risks including relapse, hospitalization, and suicide 1. The decision to continue olanzapine during pregnancy must weigh maternal benefit against neonatal risk, with the understanding that most affected neonates have mild, transient symptoms.